Research Article Details
| Article ID: | A03860 |
| PMID: | 33841814 |
| Source: | Food Sci Nutr |
| Title: | Functional beverages improve insulin resistance and hepatic steatosis modulating lysophospholipids in diet-induced obese rats. |
| Abstract: | Hypercaloric beverages increase the prevalence of insulin resistance and nonalcoholic fatty liver disease (NAFLD), diets with polyphenolic compounds improved these alterations. The study aimed to evaluate the effect of the consumption of three functional beverages (prepared with: Roselle, green tea, cinnamon, Malabar tamarind, and peppermint in different proportions) on insulin resistance and NAFLD and their relation to liver phospholipid regulation in Wistar rats fed with a high-fat and fructose (HFF) diet. The consumption of beverages showed lower liver triglycerides compared to HFF control group, being the called beverage B the successful triggering up to 30.1%. The consumption of functional beverages improved insulin resistance and decreased the abundance of LysoPC (20:2), LysoPC (16:0), LysoPC (14:0), LysoPE (18:0), LysoPC (15:0), and LysoPC (20:1), with beverage C being the one with the meaningful effect. The results indicate that the functional beverage consumption improves insulin resistance, and decrease the degree of NAFLD, these through modifications of lysophosphatidylcholines, and lipids metabolism. |
| DOI: | 10.1002/fsn3.2162 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D545 | Pig placenta extract | Biological extract | -- | -- | -- | Under clinical trials | Details |
| D258 | Omega 3 PUFA | Chemical drug | DB11133 | PPARG ligand; PPARA activator | Hypolipidemic drug | Under clinical trials | Details |
| D075 | Choline | Supplement | DB00122 | PLD2 product of; PLD1 product of | -- | Under clinical trials | Details |
| D142 | Fructose | Chemical drug | DB04173 | -- | Intravenous nutrition drug | Under clinical trials | Details |
| D079 | Cinnamon | Biological drug | DB10520 | -- | -- | Under clinical trials | Details |
| D273 | Phosphatidylcholine | Chemical drug | DB15834 | -- | -- | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D125 | Epanova | Chemical drug | DB11133 | PPARG ligand; PPARA activator | Enhance lipid metabolism | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |